Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Co. plc stock logo
AMRN
Amarin
$11.36
+2.3%
$9.88
$7.08
$17.91
$235.23M0.6676,214 shs40,308 shs
biote Corp. stock logo
BTMD
biote
$4.08
+10.9%
$3.58
$3.04
$8.44
$223.22M1.17194,005 shs338,720 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.96
+3.1%
$0.72
$0.52
$1.98
$280.35M4.214.48 million shs7.57 million shs
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
$1.43
-9.5%
$1.23
$0.85
$4.42
$65.37M1.4486,843 shs1.00 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Co. plc stock logo
AMRN
Amarin
+2.25%+2.25%+8.92%-0.72%-32.98%
biote Corp. stock logo
BTMD
biote
+10.87%+2.51%+18.95%-5.56%-35.75%
Ocugen, Inc. stock logo
OCGN
Ocugen
+3.14%+18.52%+33.48%+57.35%-45.14%
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
-9.49%-12.27%+14.40%-7.14%-53.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Co. plc stock logo
AMRN
Amarin
0.4303 of 5 stars
1.04.00.00.02.10.00.0
biote Corp. stock logo
BTMD
biote
3.2144 of 5 stars
3.52.00.00.03.33.31.3
Ocugen, Inc. stock logo
OCGN
Ocugen
1.26 of 5 stars
3.51.00.00.02.90.00.0
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
1.5627 of 5 stars
3.72.00.00.02.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Co. plc stock logo
AMRN
Amarin
2.00
Hold$7.00-38.38% Downside
biote Corp. stock logo
BTMD
biote
3.00
Buy$8.0096.08% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00525.00% Upside
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00529.37% Upside

Current Analyst Ratings Breakdown

Latest PDSB, OCGN, AMRN, and BTMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/17/2025
Amarin Co. plc stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$20.00 ➝ $7.00
3/27/2025
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $13.00
3/13/2025
biote Corp. stock logo
BTMD
biote
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
3/13/2025
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
3/7/2025
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
3/6/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $7.00
3/6/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Co. plc stock logo
AMRN
Amarin
$214.11M1.10N/AN/A$1.35 per share8.41
biote Corp. stock logo
BTMD
biote
$199.38M1.12$0.43 per share9.60($0.58) per share-7.03
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.52M62.00N/AN/A$0.16 per share6.00
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Co. plc stock logo
AMRN
Amarin
-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)
biote Corp. stock logo
BTMD
biote
$3.32M$0.6115.697.56N/A5.20%-32.41%22.26%8/14/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%8/14/2025 (Estimated)
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
-$42.94M-$0.94N/AN/AN/AN/A-139.57%-67.22%8/12/2025 (Estimated)

Latest PDSB, OCGN, AMRN, and BTMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
5/9/2025Q1 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05N/A$1.48 million
5/7/2025Q1 2025
Amarin Co. plc stock logo
AMRN
Amarin
-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A
5/7/2025Q1 2025
biote Corp. stock logo
BTMD
biote
$0.06$0.08+$0.02$0.37$47.25 million$48.99 million
3/27/2025Q4 2024
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
-$0.29-$0.21+$0.08-$0.21N/AN/A
3/12/2025Q4 2024
Amarin Co. plc stock logo
AMRN
Amarin
-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million
3/5/2025Q4 2024
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Co. plc stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
biote Corp. stock logo
BTMD
biote
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Co. plc stock logo
AMRN
Amarin
N/A
3.23
2.11
biote Corp. stock logo
BTMD
biote
N/A
1.50
1.16
Ocugen, Inc. stock logo
OCGN
Ocugen
0.04
2.58
2.58
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
0.55
2.84
2.84

Institutional Ownership

CompanyInstitutional Ownership
Amarin Co. plc stock logo
AMRN
Amarin
22.25%
biote Corp. stock logo
BTMD
biote
21.68%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
26.84%

Insider Ownership

CompanyInsider Ownership
Amarin Co. plc stock logo
AMRN
Amarin
3.30%
biote Corp. stock logo
BTMD
biote
24.00%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Co. plc stock logo
AMRN
Amarin
36020.71 million402.62 millionOptionable
biote Corp. stock logo
BTMD
biote
19454.71 million46.78 millionNot Optionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.03 million278.82 millionOptionable
PDS Biotechnology Co. stock logo
PDSB
PDS Biotechnology
2045.71 million33.86 millionOptionable

Recent News About These Companies

PDS Biotechnology (NASDAQ:PDSB) Raised to Hold at Wall Street Zen
B. Riley Increases Earnings Estimates for PDS Biotechnology
7 PDS Health updates to know

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$11.36 +0.25 (+2.25%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$11.34 -0.01 (-0.13%)
As of 05/27/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

biote stock logo

biote NASDAQ:BTMD

$4.08 +0.40 (+10.87%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.04 -0.04 (-1.10%)
As of 05/27/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$0.96 +0.03 (+3.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.96 0.00 (-0.31%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.43 -0.15 (-9.49%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.36 -0.07 (-5.17%)
As of 05/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.